HUTCHMED (China) Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HCM.L research report →
Companywww.hutch-med.com
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors.
- CEO
- Chig Fung Cheng
- IPO
- 2006
- Employees
- 1,811
- HQ
- Hong Kong, HK
Price Chart
Valuation
- Market Cap
- $1.55B
- P/E
- 53.13
- P/S
- 3.78
- P/B
- 19.61
- EV/EBITDA
- -81.13
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 11.64%
- Op Margin
- -7.14%
- Net Margin
- 83.30%
- ROE
- 37.04%
- ROIC
- -2.35%
Growth & Income
- Revenue
- $548.65M · -12.94%
- Net Income
- $457.02M · 1111.33%
- EPS
- $0.54 · 1130.07%
- Op Income
- $-54,594,386
- FCF YoY
- -352.08%
Performance & Tape
- 52W High
- $292.00
- 52W Low
- $172.00
- 50D MA
- $205.12
- 200D MA
- $218.08
- Beta
- 0.38
- Avg Volume
- 35.24K
Get TickerSpark's AI analysis on HCM.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our HCM.L Coverage
We haven't published any research on HCM.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate HCM.L Report →